Development of mavoglurant and its potential for the treatment of fragile X syndrome (Q38164021)

30 August 2017

Development of mavoglurant and its potential for the treatment of fragile X syndrome (English)

1 reference

30 August 2017

1 reference

Baltazar Gomez-Mancilla

1

1 reference

30 August 2017

Elizabeth Berry-Kravis

2

1 reference

30 August 2017

Randi Hagerman

3

1 reference

30 August 2017

Florian von Raison

4

1 reference

30 August 2017

George Apostol

5

1 reference

30 August 2017

Mike Ufer

6

1 reference

30 August 2017

Fabrizio Gasparini

7

1 reference

30 August 2017

Sébastien Jacquemont

8

1 reference

30 August 2017

language of work or name

English

0 references

publication date

20 November 2013

1 reference

Expert Opinion on Investigational Drugs

30 August 2017

1 reference

30 August 2017

23

1 reference

30 August 2017

1

1 reference

30 August 2017

125-134

1 reference

Fragile X and autism: a multicenter survey.

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Molecular and cytogenetic analyses on Brazilian youths with pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Molecular and cytogenetic analyses of autism in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Cytogenetic abnormalities and fragile-X syndrome in Autism Spectrum Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

DNA methylation represses FMR-1 transcription in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

A point mutation in the FMR-1 gene associated with fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Advances in understanding the molecular basis of FXTAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

FMR1 and the continuum of primary ovarian insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Advances in the treatment of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Psychopharmacology in fragile X syndrome--present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Fragile X: leading the way for targeted treatments in autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Mechanism-based approaches to treating fragile X

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Metabotropic glutamate receptors: physiology, pharmacology, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Understanding fragile X syndrome: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Correction of fragile X syndrome in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Health and economic consequences of fragile X syndrome for caregivers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

A prospective open-label study of aripiprazole in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Open-label add-on treatment trial of minocycline in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.857400

10.1517/13543784.2014.857400

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference